

AMENDMENTS TO THE CLAIMS

Pursuant to 37 C.F.R. 1.121 the following is a complete listing of the claims of the present application and replaces all previous versions.

Listing of the claims:

1. (Currently amended) An isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO: 1, ~~wherein said polypeptide has the following characteristics:~~
 - i) ~~preferentially binds tumour suppressor polypeptide p53 to inhibit the pro-apoptotic activity of p53 when compared to a polypeptide, or variant thereof, as represented by the amino acid sequence as shown in SEQ ID NO: 3; and~~
 - ii) ~~includes at least one amino acid residue which residue is ubiquitinated.~~
- 2-4. (Canceled)
5. (Currently amended) The polypeptide according to claim 1 wherein said amino acid sequence of said polypeptide consists of the amino acid sequence shown in SEQ ID NO: 1.
- 6-17. (Canceled)
18. (Currently amended) A ~~pharmaceutical~~ composition comprising the polypeptide of claim 1 and a pharmaceutically-acceptable carrier.
- 19-34. (Canceled)
35. (New) The polypeptide of claim 1, wherein at least one amino acid residue of ~~SEQ ID NO: 1~~ the polypeptide is ubiquitinated.
36. (New) An isolated polypeptide comprising amino acids 1-483 of SEQ ID NO: 1.
37. (New) The isolated polypeptide of claim 1 or 36, wherein the polypeptide is acetylated.

38. (New) The isolated polypeptide of claim 37, wherein the amino-terminus of the polypeptide is acetylated.

39. (New) The isolated polypeptide of claim 1 or 36, wherein the polypeptide is amidated.

40. (New) The isolated polypeptide of claim 39, wherein the carboxyl-terminus of the polypeptide is amidated.

41. (New) The isolated polypeptide of claim 1 or 36, wherein the polypeptide is a cyclic polypeptide.

42. (New) A composition comprising the isolated polypeptide of claim 37 and a pharmaceutically-acceptable carrier.